Curanex Pharmaceuticals Common Stock
CURX | NASDAQ
$5.29
+$0.35 (+7.09%)
At close: Oct 30, 2026, 3:59 PM ET
$5.10
-$0.19 (-3.63%)
Pre-market:
Nov 2, 2026, 4:00 AM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 35.04K | 34.29K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | -35.04K | -34.29K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -3.33M | -3.18M | -3.09M | -951.33K | -57.66K | -137.45K | -138.59K | -102.07K | -44.2K | -80.2K | -12.67K |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -3.29M | -3.15M | -3.07M | -954.06K | -60.35K | -137.58K | -137.16K | -99.94K | -44.2K | -80.2K | -12.67K |
Net Income | -3.29M | -3.15M | -3.07M | -954.06K | -60.35K | -137.58K | -137.16K | -99.94K | -44.2K | -80.2K | -12.67K |
Selling & General & Admin | 731.84K | 927.2K | 752.05K | 273.85K | 57.66K | 137.45K | 63.92K | 102.07K | 44.2K | 80.2K | 12.67K |
Research & Development | 2.59M | 2.26M | 2.31M | 677.47K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | n/a | -35.04K | n/a | n/a | n/a | n/a | 74.68K | n/a | n/a | n/a | n/a |
Operating Expenses | 3.33M | 3.15M | 3.06M | 951.33K | 57.66K | 137.45K | 138.59K | 102.07K | 44.2K | 80.2K | 12.67K |
Interest Expense | n/a | n/a | n/a | 4.09K | 3.09K | 1.36K | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 3.33M | 3.18M | 3.09M | 951.33K | 57.66K | 137.45K | 138.59K | 102.07K | 44.2K | 80.2K | 12.67K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 1.42M | 1.42M | 1.42M | 1.42M | 1.39M | 1.39M | 1.39M | 1.39M | 1.39M | 1.39M | 1.39M |
Shares Outstanding (Diluted) | 1.42M | 1.42M | 1.42M | 1.42M | 1.39M | 1.39M | 1.39M | 1.39M | 1.39M | 1.39M | 1.39M |
EPS (Basic) | -2.32 | -2.22 | -2.17 | -0.67 | -0.04 | -0.10 | -0.10 | -0.07 | -0.03 | -0.06 | -0.01 |
EPS (Diluted) | -2.32 | -2.22 | -2.17 | -0.67 | -0.04 | -0.10 | -0.10 | -0.07 | -0.03 | -0.06 | -0.01 |
EBITDA | -3.29M | -3.15M | -3.06M | -934.53K | -42.23K | -121.59K | -63.92K | -102.07K | -44.2K | -80.2K | -12.67K |
EBIT | -3.29M | -3.18M | -3.09M | -949.97K | -57.26K | -136.23K | -63.92K | -102.07K | -44.2K | -80.2K | -12.67K |
Depreciation & Amortization | n/a | 35.04K | 34.29K | 15.44K | 15.03K | 14.63K | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove CURX